Skip to main content
. 2021 Nov 29;12:6960. doi: 10.1038/s41467-021-26951-z

Fig. 1. RRMM samples and scRNA-seq data set.

Fig. 1

a Typical disease course of RRMM patients and sampling time-points of the study. b Workflow for scRNA-seq including CD138 sorting of myeloma cells. c Overview of scRNA-seq data analysis. Left: clustering and cell type identification was based on scRNA-seq of 212,404 cells from primary mononuclear bone marrow samples of RRMM patients (n = 20) as shown by an UMAP embedding colored by sample without batch-effect correction. Middle: myeloma cells subclones according to genetic aberrations were identified while changes of BME cells were evaluated against the HCA data set of healthy donors. Right: by integrating these data, subclone-specific interactions of myeloma cells with BME cells were revealed. d UMAP embedding as shown in panel (c) but colored according to expression of the plasma cell marker TNFRSF17. e Same as panel (d) but colored for plasma cells according to the annotation with SingleR.